High materiality7/10
Barclays Starts Ligand Pharma (LGND) at Overweight
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
LGND receives an Overweight rating from Barclays with a $345 target; current price $299.04.
- Barclays assigns Overweight on LGND with $345 target; current price $299.04.
Key facts
- 01
Target: $345
- 02
Posted price: $299.04
- 03
Analyst firm: Barclays
- 04
Analyst: Glen Santangelo
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.